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The electrochemical behavior of inclusion complexes of nifedipine (Nif) and amlodipine (Aml), a 
long-acting calcium channel blockers dihydropyridine (DHP) class, with -cyclodextrin (βCD) and (2-
hydroxypropyl)-β-cyclodextrin (HPβCD), is examined using cyclic and square wave voltammetry in 
0.05 M NaHCO3 and phosphate buffer (pH=11) on a gold electrode. The voltammograms show a 
single irreversible anodic wave with the current controlled by adsorption. It was found that phosphate 
buffer favorites the electrochemical activity of both complexes of Nif with the linear dependency of 
the oxidative currents on their concentrations. In phosphate buffer, only HPβCD-Aml complex showed 
linear dependency of the oxidative currents on the concentration. In 0.05 M NaHCO3 as electrolyte 
only HPβCD-Nif exhibited apparent activity. The initial potential of the anodic reaction as well as the 
value of the potential for anodic currents maximum of all the examined complexes in both electrolytes 
were shifted to the positive direction compared to their standards. In addition, the value of anodic 
currents decreased. 
 
 
Keywords: cyclodextrin complexes; electrochemical determination; gold electrode; cyclic 
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1. INTRODUCTION 
Nifedipine, dimethyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5-dicarboxylate, is 
a dihydropyridine calcium channel blocker. It is a peripheral and coronary vasodilator, but it has little 
or no effect on cardiac conduction and negative inotropic activity is rarely seen in therapeutic doses 
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[1,2]. After oral administration of nifedipine, arterial dilation increases peripheral blood flow, but 
venous tone does not change [3]. Nifedipine is used in the management of hypertension, angina 
pectoris, particularly when a vasospastic element is present, as in Prinzmetal's angina, but is not 
suitable for relief of an acute attack and in the treatment of Raynaud's syndrome [1].  
Amlodipine, 2-[(2-aminoethoxy)methyl]4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-
pyridinedicarboxylic acid 3-ethyl 5-methyl ester, is a second generation 1,4-dihydropyridine derivative 
of the prototypical molecule nifedipine [2]. Like most of the second generation dihydropyridine 
derivatives, it has a greater selectivity for the vascular smooth muscle than myocardial tissue, a longer 
half-life (34 hours), and less negative inotropy than the prototypical nifedipine. Amlodipine is used in 
the treatment of chronic stable angina and in the management of mild-to-moderate essential 
hypertension. It is marketed as the benzene sulfonic acid salt (besylate) [1,2,4].  
1,4-Dihydropyridine calcium channel antagonist drugs are characterized by a high tendency to 
degradation when exposed to light. Oxidative aromatization of dihydropyridine fragment to the 
pyridine moiety is one of the main degradation pathways of amlodipine and related molecules of 1,4-
dihydropyridine family (such as nifedipine) and occurs both in solution and in solid state and is 
promoted by light (Fig. 1) [5-8]. These drugs absorb intensively in the UV-A (some derivates also in 
the visible) and are known to be photolabile [8-12]. When amlodipine and corresponding besylate were 
irradiated in a solution, both in the presence and in the absence of air, it was found to give the 
aromatized pyridine as the main product [12,13]. Under exposition of nifedipine to daylight or to 
certain wavelengths of artificial light it is converted to a nitrosophenylpyridine derivative, while 
expose to ultraviolet light leads to formation of nitrophenylpyridine derivative [1,14-16]. 
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Figure 1. 1,4-Dihydropyridine oxidative degradation to pyridine derivative under the influence of light 
– amlodipine (R1=Cl; R2=COOMe; R3=COOEt; R4=CH2OCH2CH2NH2; R5=Me), nifedipine 
(R1=NO2; R2,R3=COOMe; R4,R5=Me). 
 
Photo-degradation products of amlodipine and nifedipine do not have pharmacological activity 
thus prevention of photo-degradation of their formulations is very important. For this purpose different 
kind of protective agents are used. Several formulations including cyclodextrins, liposomes and 
microspheres have been prepared and characterized [17-21]. Various organic molecules can be 
encapsulated in the cyclodextrin cavity, forming so-called inclusion complexes. Among the natural 
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cyclodextrins, α-, β- and γ-cyclodextrins consisting of 6, 7 and 8 D-glucopyranose units, respectively 
are the most frequently used for these purpose. The glucosidal units are linked by α-1,4 glycoside links 
to form the cyclic structures [22,23].  
The inclusion complexes (Fig. 2) of nifedipine with β-cyclodextrin [24] (βCD-Nif) or (2-
hydroxypropyl)-β-cyclodextrin (HPβCD-Nif) and amlodipine besylate with β-cyclodextrin (βCD-Aml) 
or (2-hydroxypropyl)-β-cyclodextrin [25] (HPβCD-Aml) were prepared in solid state by co-
precipitation with 1:1 mol ratio and characterized by the application of spectroscopic methods FTIR, 
1
H-NMR and XRD. Formation of inclusion complexes with cyclodextrin alters the physical properties 
of the included components such as solubility, dissolution rate, photo-sensitivity and stability [17,24-
29]. 
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Figure 2. Structure of β-cyclodextrin (βCD) (R=H) and (2-Hydroxypropyl)-β- cyclodextrin (HPβCD) 
(R=CH2CH2(OH)CH3); Nif = nifedipine, Aml = amlodipine 
    
The aim of the work is the investigation of the electrochemical activity of inclusion complexes 
as well as the possibility of their determination on gold electrode in phosphate buffer (pH=11) and in 
0.05 M NaHCO3 using cyclic voltammetry and square wave voltammetry. The changes of the values of 
the initial oxidative potential as well as of the potential and of the value of anodic currents maximum 
of inclusion complexes compared to the amlodipine and nifedipine standards were also studied. 
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2. EXPERIMENTAL 
2.1. Materials 
Nifedipine and amlodipine besylate (pure substance) were kindly provided by Zdravlje Actavis 
Company, Leskovac, Serbia. Complexing agents β-cyclodextrin and (2-hydroxypropyl)-β-cyclodextrin 
of purity 98% and 97.5% were purchased by Merck, Darmstadt and Sigma-Aldrich, Wisconsin, 
respectively. Potassium dihydrogen phosphate (KH2PO4xH2O), and NaHCO3 were p.a. purity, 
obtained from Merck. Potassium hydroxide was p.a. purity obtained from J. T. Baker. HPLC grade of 
methanol and acetonitrile were purchased from J.T. Baker. Ammonium acetate and orthophosphoric 
acid were purchased from Merck. For preparing solution of ammonium acetate purified water was 
used. Water was purified by Milli-Q system. 
 
2.2. Preparation of standard and stock solutions 
Standard stock solution of nifedipine in acetonitrile (c=0.604 mg mL
-1
) and standard stock 
solution of amlodipine besylate in mobile phase (c=0.612 mg mL
-1
) were used. Working solutions of 
nifedipine and amlodipine besylate were prepared by diluting of stock solutions with acetonitrile or the 
mobile phase, respectively. These solutions were used to obtain the calibration graph for HPLC 
analysis. 
 
2.3. Preparation of inclusion complexes by co-precipitation 
2.3.1. Inclusion complex formed by nifedipine with cyclodextrin 
Nifedipine (1 mmol, 346 mg) and β-cyclodextrin (1 mmol, 1135 mg) or 2-hydroxypropyl-β-
cyclodextrin (1 mmol, 1540 mg) were mixed and dissolved in 150 mL of purified water. The light-
protected solution was mixed at room temperature for 24 hours, evaporated in a vacuum evaporator at 
50 °C to approx. 20 mL volume, and then dried at a temperature 25 °C in a desiccator above 
concentrated sulphuric acid. After drying the obtained crystalline complexes are used as such for 
further investigation [24]. 
 
2.3.2. Inclusion complex formed by amlodipine besylate with cyclodextrin 
Amlodipine besylate (1 mmol, 567 mg) and β-cyclodextrin (1 mmol, 1135mg) or 2-
hydroxypropyl-β-cyclodextrin (1 mmol, 1540 mg) were mixed and dissolved in 150 mL of purified 
water. The light-protected solution was mixed at room temperature for 24 hours, evaporated in a 
vacuum evaporator at 50 °C to approx. 20 mL volume, and then dried at a temperature 25 °C in a 
desiccator above concentrated sulphuric acid. After drying the obtained crystalline complexes are used 
as such for further investigation [25]. 
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The whole process is performed in darkness in order to protect nifedipine or amlodipine 
besylate from photodegradation. The molar ratio in the formed complexes of nifedipine or amlodipine 
besylate with complexing agents (β-cyclodextrin or 2-hydroxypropyl-β-cyclodextrin) is 1:1. 
 
2.4. Cyclic voltammetry 
Standard equipment was used for the cyclic voltammetry (CV) measurements and the three 
electrode electrochemical cell was described in detail previously [30].  
Polycrystalline gold served as the working electrode, a gold wire was used as the counter 
electrode and a saturated calomel electrode as the reference electrode. Polycrystalline gold (Pine 
rotating disc, used as stationary electrode, surface area 0.500 cm
2
) was polished with diamond paste, 
cleaned with a mixture of purified water and sulfuric acid and further cleaned with purified water in an 
ultrasonic bath. All the potentials are given vs. SCE. Prior to the addition of cyclodextrin complexes 
the electrolyte was deoxygenated by purging with nitrogen. All the experiments were performed at 
room temperature. After the addition of inclusion complexes, only the first sweep is recorded and the 
electrode is polished and cleaned between the two consecutive investigated concentrations. 
 
2.5. Square wave voltammetry 
Square wave voltammetry (SWV) measurements were performed using AUTOLAB 
potentiostat/galvanostat (Metrohm, ECO Chemie, The Netherlands). The operating parameters were: 
potential step of 2 mV, pulse of 20 mV, frequency 8 Hz and scan rate 15 mV s
–1
.  
 
2.6. Preparation of the standard solutions for the analysis of complexes 
Appropriate amount of inclusion complexes was weight and dissolved in purified water or 
purified water-methanol mixture 1:1. Complexes with -cyclodextrin were dissolved in warm water 
while complexes with 2-hydroxypropyl--cyclodextrin were dissolved at room temperature. For 
complexes with nifedipine water-methanol mixture 1:1 were used. 
 
2.7. Equipment and chromatographic conditions 
2.7.1. Apparatus 
HPLC system (Agilent 1100 Series) equipped with binary pump, Diode Array Detector, 
column thermostat and the thermostatted autosampler was used. ChemStation 32 software was used for 
the data acquisition.  
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2.7.2. HPLC analysis of nifedipine-cyclodextrin complexes 
Hypersil ODS column (Agilent, 250.0 mm x 4.6 mm id, 5 µm particle size) and the mobile 
phase consisted of acetonitrile and 0.03% v/v solution of orthophosphoric acid (40:60, v/v) was used. 
pH of mobile phase was 2.67. The flow rate was maintained at 1.0 mL/min. The mobile phase was 
passed through 0.45 µm membrane filter (Sartorius Stedim Biotech GmbH, Goettingem, Germany) 
and degassed before use. The elution was monitored with diode array detector at 235 nm. The injection 
volume was 20 µL. The test was carried out protected from light. All the chromatographic separations 
were carried out at controlled room temperature (20-25 °C). 
 
2.7.3. HPLC analysis of amlodipine besylate-cyclodextrin complexes  
The Spherisorb ODS1 (octadecylsilyl silica gel) column (Waters, 250.0 mm x 4.0 mm id, 5 µm 
particle size) and the mobile phase consisting of 2.3 g/L ammonium acetate solution - methanol (30:70, 
v/v) was used. The flow rate was maintained at 1.0 mL min
–1
. The mobile phase was passed through 
0.45 µm membrane filter (Sartorius Stedim Biotech GmbH, Goettingem, Germany) and degassed 
before use. The elution was monitored with diode array detector at 237 nm. The injection volume was 
20 µL. The test was carried out protected from light. All the chromatographic separations were carried 
out at controlled room temperature (20-25 °C). 
 
 
 
3. RESULTS AND DISCUSSION 
The oxidative behavior of inclusion complexes of HPβCD-Aml, βCD-Aml, HPβCD-Nif and 
βCD-Nif was studied in the same way as for amlodipine standard determination [31]. 
 
3.1. Cyclic voltammetry and square wave voltammetry of cyclodextrin complexes with  
nifedipine in phosphate buffer 
Cyclic voltammograms of βCD-Nif are presented in Fig. 3 in phosphate buffer (pH=11) 
showing that in anodic direction its electrooxidation begins at 0.25 V with the increasing tendency 
until the current maximum appearing at the beginning of the oxide formation on gold electrode. This 
maximum current value appears in the whole range of the oxide formation with slightly increasing 
from 0.9 V to 1.0 V. In cathodic direction the presence of βCD-Nif leads to the smaller currents of the 
oxide reduction which is attributed to the reduction of the species oxidized in anodic direction.  
The linear dependency of anodic currents vs. concentration of nifedipine in βCD-Nif in a range: 
2.24 – 5.53 µg mL-1 was obtained at 0.77 V from the data in Fig. 3. The mentioned linear relationship 
corresponds to the equation 1 given in Table 1 [32].  
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Figure 3. Cyclic voltammogram of gold electrode in phosphate buffer (pH=11) (dashed line) and in a 
presence of βCD-Nif. Nifedipine concentration: a) 2.24 µg mL-1, b) 3.35 µg mL-1, c) 4.44 µg 
mL
-1, d) 5.53 µg mL-1, sweep: 50 mV s–1; nifedipine standard 2.7 µg mL-1 (dotted line). 
 
 
Table 1. The linear dependency of anodic currents vs. concentration of nifedipine and amlodipine in 
studied complexes 
No. Complex Buffer Method Equation, j/mA cm
–2
=f(C/µg mL-1) R 
1 βNa Phd CV j =0.1226 (±0.0025)+0.0098 (±0.0006) C  0.9962 
2 βN Ph SWV jpa=0.0876 (±0.0003) + 0.0019 (±0.00004) C 0.9998 
3 HN
b
 Ph CV j=0.1453 (±0.0018)+0.0258 (±0.0006) C  0.9996 
4 HN Ph SWV jpa=0. 0727 (±0.0039) + 0.0069 (±0.0014) C  0.9802 
5 HN SBC
e
 CV j=0.0782 (±0.0021)+0.0333 (±0.0011) C  0.9995 
6 HN SBC SWV jpa=0.0706 (±0.0004)+0.0021 (±0.0001) C  0.9986 
7 HA
c
 Ph CV j=0.0679 (±0.0030)+0.0132 (±0.0004) C 0.9994 
8 HA Ph SWV j=0.0353 (±0.0008)+0.0006 (±0.00006) C 0.9885 
a
 βCD-Nif; b HPβCD-Nif; c HPβCD-Aml; d phosphate buffer; e 0.05 M NaHCO3 
 
Square wave voltammetry, as a fast, sensitive technique with low detection limit, was used for 
quantitative determination of nifedipine in βCD-Nif on the gold electrode. The square wave anodic 
stripping voltammograms for different concentrations of nifedipine in βCD-Nif, recorded in phosphate 
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buffer in the potential range from 0 to 1.0 V at the scan rate of 15 mV s
–1
 are presented in Fig. 4. 
Before each scan, the compound was accumulated at the electrode surface at 0.1 V during 180 s. Each 
voltammogram is characterized by the well defined peak at approximately 0.45 V and it is attributed to 
the oxidation of adsorbed inclusion complex. The current of anodic stripping peak exhibits linear 
dependence on the βCD-Nif concentration. 
The linear dependency of anodic peak currents vs. concentration of nifedipine in βCD-Nif in a 
range: 4.44 – 8.72 µg mL–1 was obtained from the data in Fig. 4. The linear relationship is given by the 
equation 2 given in Table 1.  
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Figure 4. Square wave anodic stripping voltammograms at gold electrode in phosphate buffer (pH=11) 
and in a presence of βCD-Nif. Nifedipine concentration: a) 4.44 µg mL-1, b) 6.66 µg mL-1, c) 
8.72 µg mL-1. Accumulation time: 220 s at E = 0.1 V; step size 2 mV, pulse size 20 mV, 
frequency 8 Hz, scan rate 15 mV s
–1
. 
 
Cyclic voltammograms of HPβCD-Nif presented in Fig. 5 in phosphate buffer (pH=11) show 
the same electrochemical behavior as was observed for βCD-Nif (Fig. 3).  The linear dependency of 
anodic currents vs. concentration of nifedipine in HPβCD-Nif in a range: 1.82 – 3.60 µg mL-1 was 
obtained at 0.65 V from the data given in Fig. 5. The linear relationship corresponds to the equation 3 
(Table 1). 
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Figure 5. Cyclic voltammogram of gold electrode in phosphate buffer (pH=11) (dashed line) and in a 
presence of HPβCD-Nif. Nifedipine concentration: a) 1.82 µg mL-1, b) 2.71 µg mL-1, c) 3.60 
µg mL-1, sweep: 50 mV s–1; nifedipine standard 2.7 µg mL-1 (dotted line).  
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Figure 6. Square wave anodic stripping voltammograms at gold electrode in phosphate buffer (pH=11) 
and in a presence of HPβCD-Nif. Nifedipine concentration: a) 1.82 µg mL-1, b) 2.71 µg mL-1, 
c) 3.60 µg mL-1. Accumulation time: 180 s at E = 0.1 V; step size 2 mV, pulse size 20 mV, 
frequency 8 Hz, scan rate 15 mV s
–1
.  
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Quantitative determination of nifedipine in HPβCD-Nif on the gold electrode was also 
performed by square wave voltammetry. SWV of HPβCD-Nif showed similar behavior as βCD-Nif 
under the same experimental conditions. The results are presented in Fig. 6. Again, each 
voltammogram is characterized by the well defined peak at approximately 0.45 V and it is attributed to 
the oxidation of adsorbed inclusion complex. The current of anodic stripping peak exhibits linear 
dependence on the HPβCD-Nif concentration in a range: 1.82 – 3.60 µg mL-1. The mentioned linear 
relationship corresponds to the equation 4 (Table 1). 
 
3.2. Cyclic voltammetry and square wave voltammetry of cyclodextrin complexes with  
nifedipine in 0.05 M NaHCO3 
Although, we have showed earlier [31] that the phosphate buffer is more suitable for the anodic 
oxidation of dihydropyridine class drugs, we tested 0.05 M NaHCO3 as electrolyte as well. All the 
examined inclusion complexes exhibited apparently lower electrochemical activity than in phosphate 
buffer. The lower activity but good linearity of the currents vs. concentrations was observed only in the 
case of the HPβCD-Nif. The linear dependency of anodic currents vs. its concentrations appears at 300 
mV more positive potential than was the case in phosphate buffer (Figs. 5 and 7). The linear 
dependency in a range: 0.91 – 2.71 µg mL-1 obtained at 0.95 V from the data in Fig. 5 is given in Table 
1 by the equation 5.  
 
 
 
Figure 7. Cyclic voltammogram of gold electrode in 0.05 M NaHCO3 (dashed line) and in a presence 
of HPβCD-Nif (full line). Nifedipine concentration: a) 0.91 µg mL-1, b) 1.82 µg mL-1, c) 2.71 
µg mL-1, sweep: 50 mV s–1; nifedipine standard 2.7 µg mL-1 (dotted line). 
 
Square wave voltammetry showed also the lower electrochemical activity of nifedipine in 
HPβCD-Nif in 0.05 M NaHCO3 (lower anodic currents) (Fig. 8) than in phosphate buffer (Fig. 6). Each 
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voltammogram is characterized by the well defined peak at approximately 0.6 V which is more than 
100 mV shifted to the positive potential comparing to phosphate buffer. The linear dependency of peak 
currents vs. concentration of nifedipine in HPβCD-Nif in a range: 0.91 – 2.71 µg mL-1 is presented by 
the equation 6 (Table 1). 
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Figure 8. Square wave anodic stripping voltammograms at gold electrode in 0.05 M NaHCO3 and in a 
presence of HPβCD-Nif. Nifedipine concentration: a) 0.91 µg mL-1 L-1, c) 2.71 
µg mL-1. Accumulation time: 180 s at E = 0.1 V; step size 2 mV, pulse size 20 mV, frequency 8 
Hz, scan rate 15 mV s
–1
. 
 
3.3. Cyclic voltammetry and square wave voltammetry of cyclodextrin complexes with  
amlodipine in phosphate buffer 
In the form of inclusion complexes amlodipine exhibited much lower electrochemical activity 
in both electrolytes compared to nifedipine complexes. Only HPβCD-Aml in phosphate buffer 
exhibited one apparent electrochemical activity as is presented in Fig. 9. Cyclic voltammograms show 
an increase in anodic activity in the whole area of the oxide formation on gold electrode with the linear 
dependency on the concentrations at 0.85 V.  The linear dependency of peak currents vs. concentration 
of amlodipine in HPβCD-Aml in a range: 3.26 – 9.58 µg mL-1 is presented by the equation 7 (Table 1). 
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Figure 9. Cyclic voltammogram of gold electrode in phosphate buffer (pH=11) (dashed line) and in a 
presence of HPβCD-Aml. Amlodipine concentration: a) 3.26 µg mL-1, b) 6.45 µg mL-1, c) 9.58 
µg mL-1, sweep: 50 mV s–1. 
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Figure 10. Square wave anodic stripping voltammograms at gold electrode in phosphate buffer 
(pH=11) and in a presence of HPβCD-Aml. Amlodipine concentration: a) 9.58 µg mL-1, b) 
11.13 µg mL-1, c) 12.65 µg mL-1, d) 14.17 µg mL-1. Accumulation time: 180 s at E = 0.1 V; 
step size 2 mV, pulse size 20 mV, frequency 8 Hz, scan rate 15 mV/s. 
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Square wave voltammetry showed the apparent electrochemical activity of amlodipine in 
HPβCD-Aml in the phosphate buffer (Fig. 10). As cyclic voltammograms show, the linear dependency 
was recorded at 0.85 V. The linear dependency in a range: 9.58 – 14.17 µg mL-1 is presented by the 
equation 8 (Table 1).The values of the all concentrations of nifedipine and amlodipine in studied 
complexes (by CV and SWV) as is presented in Tab 1 are confirmed by HPLC method. 
The characterization of cyclodextrin (CD) systems by electrochemical methods, mainly by 
cyclic voltammetry has been discussed [33-36] with the opinion that the presence of CD in the 
electrolyte solution causes a decrease in the peak current and also a shift in the apparent half-wave 
potential in cyclic voltammetry. 
Comparing to the electrochemical behavior of Aml [31]
 
and Nif standards under the identical 
experimental conditions it was observed for all the examinated complexes that the complexation 
causes two main changes in cyclic voltammograms in both electrolytes. For example, this can be 
shown by comparison of the HPβCD-Nif (full line) and Nif standard (dotted line) (Figs. 5 and 7). 
Firstly, the initial potential of the anodic reaction is shifted to the positive direction, the value of the 
potential for the obtained linearity of the anodic currents vs. concentrations is also shifted to the 
positive direction and secondly, the value of anodic currents decreased.
 
These changes in all the 
discussed inclusion complexes [33-36] are ascribed to the inclusion complexes formed and in a case 
presented in Fig. 7, to the formed HPβCD-Nif. 
The change in the initial potential reveals that amlodipine and nifedipine molecules bonded in 
complexes were oxidized with more difficulty. For example, in a case of indapamide and its 
complexation with β-cyclodextrin anodic peak was also shifted to the more positive potential 
comparing to indapamid and anodic currents decreased [37]. The same effect (the potential shift to the 
more negative value during the electroreduction and the currents decrease was observed for the 
inclusion complex of β-cyclodextrin and furnidipine [38]. A decrease in the electrochemical response 
was also observed during in-vivo evaluation of the controlled release effects of the mediator- β-
cyclodextrin complexes to microbial delivery [39]. 
By comparing the chemical structures of amlodipine and nifedipine, it is evident that presence 
of NO2 group with a strong hydrophobic effect (coefficient hydrophobic substituent, =-0.85 [40]) 
significantly decrease the total hydrophobic characteristics of nifedipine.  On the other hand, the 
presence of Cl group as substituent (=+0.36 [40]) increase the hydrophobic properties of amlodipine. 
It is important to note that the contribution of the hydrophobic effect to drug/CD complex stability is 
evident and significant but varies with the structure of drug species [41]. These facts are in good 
agreements with our experimental data that HPβCD-Aml complex is more subjected to 
electrochemical adsorption and accumulation. 
 
 
 
4. CONCLUSION 
It was shown by cyclic voltammetry and square wave voltammetry that phosphate buffer 
favorites the electrochemical activity of inclusion complexes of  nifedipine  and an apparent 
electrochemical activity and the linear dependency of the oxidative currents on concentrations of 
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HPβCD-Nif and βCD-Nif was found. The electrochemical activity of nifedipine incorporated in 
complexes is independent of the type of cyclodextrin complex. 
By testing 0.05 M NaHCO3 as electrolyte, nifedipine inclusion complexes exhibited much 
lower electrochemical activity than in phosphate buffer. The good linearity of the currents versus 
concentrations is observed only in the case of the HPβCD-Nif but with the two times lower currents in 
the area of the oxide formation.  
The phosphate buffer favorites only HPβCD-Aml, with the linear dependency of the oxidative 
currents on concentrations. By testing 0.05 M NaHCO3 as electrolyte amlodipine inclusion complexes 
exhibited the low activity as well as the absence of the linearity of the anodic currents 
vs.concentrations. 
It was observed that complexation with amlodipine and nifedipine in all the cases causes two 
main changes in cyclic voltammograms compared to their standards. Firstly, the initial potential of the 
anodic reaction as well as the value of the potential for anodic currents maximum is shifted to the 
positive direction. Secondly, the value of anodic currents decreases. These effects are attributed to the 
inclusion complexes formed and confirmed their successful formation. 
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